Slide 1: Initial Results from the Phase 1/2 Trial of the T Cell SARS-CoV-2 Vaccine Candidate VB10.2210
Initial Results from the Phase 1/2 Trial of the T Cell SARS-CoV-2 Vaccine Candidate VB10.2210 September 27, 2022
Slide 2: Forward-looking statement
Forward-looking statement This announcement and any materials distributed in connection with this presentation may contain certain forward- looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company’s current expectations and assumpt
Slide 3: Nykode and Adaptive's technologies provide a potential synergistic collaboration
Nykode and Adaptive’s technologies provides a potential synergistic collaboration Rapidly identify Proven technology to broadly immunogenic optimize T cell T cell epitopes responses to through TCR antigens included in sequencing from the APC targeted clinical samples vaccine Synergistic collaboratio
Slide 4: Executive Summary
Executive Summary • VB10.2210 is a novel SARS-CoV-2 vaccine candidate designed to induce T cell responses against validated epitopes in Spike and seven additional viral proteins conserved across variants of concern • The safety and ability of VB10.2210 to induce T cell responses up until day 35 were
Slide 5: Rationale for a T cell-based vaccine
Rationale for a T cell-based vaccine • Increasing evidence of the importance of broad T cell MECHANISM OF ACTION responses against COVID-19: • Pre-existing T cell responses associated with protection against disease in previously seronegative individuals • CD8+ T cells recognize viral • Non-delayed
Slide 6: VB10.2210 includes a large set of 96 validated and conserved viral T cell epitopes
VB10.2210 includes a large set of 96 validated and conserved viral T cell epitopes • High mutational drift in Spike are likely to affect both Spike-specific antibody and T cell Targeting unit: responses CCL3L1 • VB10.2210 is designed to induce T cell responses against Spike and seven additional anti
Slide 7: First-in-human trial investigating VB10.2210 as booster in previously vaccinated subjects
First-in-human trial investigating VB10.2210 as booster in previously vaccinated subjects A Phase 1/2, open label, dose escalation trial to determine safety and of the T-cell candidate (VB10.2210) (NCT05069623) Booster in COVID-19 naïve healthy adults (18-60y) Vaccinated with at least 2 doses mR
Slide 8: VB10.2210 was safe and well tolerated
VB10.2210 was safe and well tolerated • VB10.2210 was safe and well tolerated up to the highest dose of 3 mg with no dose limiting adverse events • No fatal adverse events, no serious adverse events, or no adverse events of special interest were reported • Local reactions were mainly mild injection
Slide 9: Novel T cell vaccine induces responses against conserved epitopes in Spike and non-Spike of SARS-CoV-2
VB10.2210 novel T cell vaccine induces T cell responses against conserved epitopes in Spike and non-Spike of SARS-CoV-2 Spike epitopes non-Spike epitopes • T cell responses were analyzed by Dose LEVEL 3 (N=11) Dose LEVEL 3 (N=11) ex vivo ELISpot up until day 35 400 2000 1000 • VB10.2210 amplified re
Slide 10: VB10.2210 induces response to all 5 peptide pools from Spike and non-Spike
VB10.2210 induces response to all 5 peptide pools from Spike and non-Spike Response > 1 peptide pool 82% 82% Spike 16% Membrane 18 % 18 % 20% • 82 % (9/11) of the subjects vaccinated with VB10.2210 responded to at least 1 peptide pool 9% Nucleocapsid • All peptide pools in VB10.2210 vaccine ORF7 16%
Slide 11: T cell responses induced de novo to all four non-Spike antigens conserved across variants
VB10.2210 induced de novo T cell responses to all four non-Spike antigens conserved across SARS-CoV-2 variants SPIKE EPITOPES M EPITOPES N epitopes ORF 1ab, 3, 10 epitopes ORF 7 EPITOPES PP2 400 200 1000 200 2000 150 1500 100 500 1000 IFNγ (SFU/106 cells) IFNγ (SFU/106 cells) IFNγ (SFU/106 cells) IF
Slide 12: T cell responses induced by a single DNA vaccination further boosted by a second vaccination
VB10.2210 induces T cell responses by a single DNA vaccination further boosted by a second vaccination Subject #4 Subject #9 • A single injection of VB10.2210 vaccine in pre- vaccinated subjects induced 500 1000 a strong T cell response 400 IFNγ (SFU/106 cells) • T cell responses were further IFNγ (
Slide 13: T cell responses dominated by polyfunctional CD8+ T cells
Preliminary data indicates that the T cell responses are dominated by polyfunctional CD8+ T cells Negative control • CD4/CD8 distribution determined in 5 patients. • A dominant CD8 response observed in all 5 patients Baseline Peak Non-Spike epitopes in N, M, ORFs Responses to VB10.2210 were dominate
Slide 14: Conclusions and next steps
Conclusions and next steps • Successful proof of concept for the combination of Nykode’s APC-targeted Vaccibody technology with T cell epitopes from SARS-CoV-2 selected by Adaptive Biotechnologies • Confirms the ability of Nykode’s platform to generate broad T cell responses dominated by CD8 T cells
Slide 15: Acknowledgements
Acknowledgements Thank you We would like to thank the participants as well as investigators for their participation in the trial 12 MONTHS Nykode Therapeutics | Company Presentation | Non-confidential 15
Slide 16: Unlocking the Future of Medicine
UNLOCKING THE FUTURE OF MEDICINE Contact: Agnete Fredriksen CBO IR@vaccibody.com Nykode Therapeutics | Company Presentation | Non-confidential